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Cellular reprogramming technology holds great potential for tissue repair and
regeneration to replace cells that are lost due to diseases or injuries. In addition
to the landmark discovery of induced pluripotent stem cells, advances in cellular
reprogramming allow the direct lineage conversion of one somatic cell type to another
using defined transcription factors. This direct reprogramming technology represents a
rapid way to generate target cells in the laboratory, which can be used for transplantation
and studies of biology and diseases. More importantly, recent work has demonstrated
the exciting application of direct reprogramming to stimulate regeneration in vivo,
providing an alternative approach to transplantation of donor cells. Here, we provide an
overview of the underlying concept of using cellular reprogramming to convert cell fates
and discuss the current advances in cellular reprogramming both in vitro and in vivo, with
particular focuses on the neural and retinal systems. We also discuss the potential of
in vivo reprogramming in regenerative medicine, the challenges and potential solutions
to translate this technology to the clinic.
Keywords: cell reprogramming, retina, neuroregeneration, direct reprogramming, in vivo reprogramming,
regenerative medicine, gene therapeutics
BACKGROUND
During development, cellular identity, and differentiation potential are largely determined by the
lineage history of the specific cell. Generally, the cell identity or the differentiated state of an adult
cell is remarkably stable, and only stem cells with multipotent/pluripotent potential possess the
ability to turn into another cell type(s). By transferring the somatic cell nucleus into an enucleated
oocyte in Xenopus, the Nobel Prize-winning work of Gurdon (1962) first demonstrated that mature
cells can be reprogrammed back to an embryonic state and became pluripotent. Similar nuclear
transfer was subsequently demonstrated in mammals, including Dolly the cloned sheep. These
pioneering studies provided evidence that reprogramming factors in the oocyte cytoplasm can
overwrite the cellular identity encoded in the nucleus of a fully differentiated cell (Campbell et al.,
1996). However, the precise factors that enables cell fate conversion in mature cells remain largely
elusive. The seminal work of Shinya Yamanaka’s group identified the precise signals required for
cellular reprogramming, and showed that a cocktail of four transcription factors (Oct4, Sox2, c-Myc,
and Klf4) are sufficient to reprogram skin fibroblasts into induced pluripotent stem (iPS) cells that
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resemble a primitive embryonic state (Takahashi and Yamanaka,
2006). Since then, there has been intensive research on the
identification of the precise transcription factors to alter and
reprogram cell fates.
Beyond iPS cell reprogramming, direct conversion of one
somatic cell type to an unrelated cell type can occur without
passing through an intermediate multipotent state. This direct
reprogramming approach, also known as ‘transdifferentiation,’
was first demonstrated with the conversion of fibroblasts into
myoblasts by overexpression of a single transcription factor
MyoD. This highlighted the potential power of controlling cell
fates using genetic factors (Davis et al., 1987). Another early
example of direct reprogramming was conducted by Kulessa
et al. (1995) who successfully reprogrammed myoblasts into
eosinophils and thromboblasts by forceful overexpressing of
GATA1.
In recent years, direct reprogramming has attracted enormous
interest, yielding promising results in the conversion across
multiple lineages to generate neurons, oligodendrocytes,
cardiomyocytes, muscle cells, blood progenitors, and hepatocytes
(Ladewig et al., 2013). Notably, this direct reprogramming
process is potentially much faster than generating iPS cells and
subsequent differentiation into the target cell types, which could
take months. Thus, it represents a faster and more cost-effective
method to generate cells in vitro. The concept of taking patient’s
cells and turning them into a different cell type is very attractive
for tissue engineering and regenerative medicine, as it eliminates
the risk of immune-rejection of the reprogrammed cells following
transplantation. This direct reprogramming approach also has
the potential to generate disease models using the patient’s cells,
allowing the study of disease mechanism as well as providing an
in vitro platform for drug discovery, toxicology study and testing
of gene therapy (Figure 1A). Moreover, the application of direct
reprogramming in vivo would allow us to reprogram endogenous
cells within the body to become new cell types, providing a novel
strategy to regenerate cells that are lost in diseases or injuries
(Figure 1B).
In this review we will discuss both the in vitro and in vivo
application of direct reprogramming, its clinical implementation
in regenerative medicine, the future directions and the current
challenges to translate this technology into clinical practice.
DIRECT REPROGRAMMING TO
GENERATE NEURONS IN VITRO
The underlying concept of cellular reprogramming is that
the transcriptome plays an important role in defining cellular
identity, hence alteration of the transcriptome to a profile
specific to the target cell type would allow us to control
and convert cell fate. Many reprogramming studies utilized a
‘defined transcription factors’ approach, where a combination
of transcription factors, usually master regulators during
development, were used to alter the transcriptome and effectively
reprogram cell fates. Here we will discuss recent reprogramming
studies in conversion of cell lineages, with a focus on
transcription factor-based reprogramming studies. However, it
should be noted that other reprogramming approaches have
also been described, such as the use of microRNA and small
molecules for cellular reprogramming which were reviewed in
details recently by others (Janowska et al., 2018; Li et al., 2018;
Lu and Yoo, 2018).
In a landmark study, Vierbuchen et al. (2010) showed that
Ascl1, a proneural master regulator in neuron specification,
can be used in combination with two other factors (Brn2,
Mytl1), to reprogram mouse fibroblasts into induced Neurons
(iN). These iN expressed neuronal markers and have the
ability to form functional synapses (Vierbuchen et al.,
2010). Subsequent studies demonstrated the generation of
iN from human embryonic fibroblast, using ASCL1, BRN2,
MYTL1 with the addition of NEUROD1 (Pang et al., 2011),
which is a helix-loop-helix transcription factor that plays
an important role in neuronal development. Notably, the
derived human iN are capable of synapse formation and
possess a functional electrophysiological profile indicative of
immature neurons. Further study demonstrated that Ascl1
solely is sufficient to reprogram fibroblasts to excitatory iN
(Chanda et al., 2014). These results established Ascl1 as a
powerful reprogramming factor for iN generation. Although
Brn2 and Mytl1 are not required for iN reprogramming, the
two factors play a role in enhancing early maturation of iN
reprogramming.
It should be noted that the derived iN are often a mixed
population of neuron subtypes, often a mix of GABAergic or
glutamatergic neurons. Other transcription factors have been
identified for direct reprogramming into neuronal subtypes.
For instance, both human and mouse fibroblasts can be
reprogrammed into dopaminergic neurons with functional
electrophysiology using Ascl1, Nurr1, and Lmx1a (Caiazzo
et al., 2011). Importantly, this reprogramming process has been
used to generate dopaminergic neurons from a Parkinson’s
disease patient, which demonstrated the potential to use
direct reprogramming for disease modeling (Figure 1A). Other
studies have identified additional reprogramming factors for
dopaminergic neuron reprogramming, including Foxa2, Brn2
(Pfisterer et al., 2011) and Pitx3 (Kim et al., 2011). Moreover,
fibroblasts can be reprogrammed into dopaminergic neurons
using a cocktail of five transcription factors, ASCL1, NGN2,
SOX2, NURR1 and PITX3, with a reported 40% efficiency in
generation of dopaminergic neuron-like cells positive for dopa
decarboxylase expression. The reprogrammed neurons exhibited
an electrophysiological profile that is dependent of the D2
autoreceptor, thus providing evidence that the reprogrammed
neurons are functionally similar to dopaminergic neurons
(Liu et al., 2012). In another example, motor neurons can
be generated using a similar direct reprogramming strategy.
Son et al. (2011) demonstrated that a complex mix of
Ascl1, Brn2, Mytl1, Ngn2, Lhx3, Isl1, and Hb9 or Neurod1
allow the reprogramming of fibroblasts into motor neurons.
Additional work showed the role of Sox11 in facilitating this
reprogramming process (Liu et al., 2013). Similarly, the feasibility
of generating sensory neurons has also been demonstrated
using direct reprogramming. Brn3a, Ngn1, or Ngn2 allowed the
reprogramming of fibroblasts into peripheral sensory neurons
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FIGURE 1 | Potentials of cellular reprogramming (A) in vitro and (B) in vivo for regenerative medicine, disease modeling, as well as drug discovery and testing gene
therapy.
that include a subset that respond similarly to itch- and
pain-sensing neurons (Blanchard et al., 2015). On the other
hand, Ascl1, Brn2, Mytl1, Ngn1, Isl2, and Klf7 have been
utilized for direct reprogramming to generate noxious stimulus-
detecting neurons with a characteristic inflammatory peripheral
sensitization response (Wainger et al., 2015).
Also, emerging evidences have supported feasibility of using
miRNAs for cellular reprogramming. Similar to transcription
factors, miRNAs are also able to target large networks of
genes and epigenetic regulators of the chromatin (Rajman
and Schratt, 2017). In particular, overexpression of the neural-
enriched miRNA, miR-9/9∗ and miR-124, allowed the direct
reprogramming of human fibroblasts into functional neurons
(Yoo et al., 2011). This reprogramming process can be further
enhanced by the addition of NEUROD2, ASCL1 and MYT1L,
which supported an important role of the miR-9/9∗-124 signaling
in neuronal reprogramming. Furthermore, miRNA-mediated
reprogramming to generate specific neuronal subtypes is also
possible. A follow-up study by the same group showed that
this miRNA-mediated reprogramming process can be directed
to generate striatal medium spiny neurons, by addition of
four other transcription factors: BCL11B, DLX1, DLX2, and
MYT1L (Victor et al., 2014). On the other hand, co-expression
of miR-9/9∗-124 with two other transcription factors, ISL1
and LHX3, promote reprogramming of human fibroblasts to
motor neurons (Abernathy et al., 2017). Similarly, miR124
can also be used with other transcription factors (ASCL1,
NURR1, LMX1A) for neuronal reprogramming to generate
human dopaminergic neurons (Jiang et al., 2015). Recent studies
have provided insights into the mechanism by which miR-9/9∗-
124 promote neuronal reprogramming. There are evidences to
support that miR09/9∗-124 promote neuronal reprogramming
by reducing activity of the transcriptional repressor REST, which
in turn reconfigure chromatin accessibility to allow expression
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of neuronal genes (Abernathy et al., 2017; Drouin-Ouellet et al.,
2017; Lee et al., 2018). Collectively, these studies support an
important role of miRNA in the conversion of cell fate to
neurons.
Furthermore, small molecules have been identified to
complement transcription factor-based direct reprogramming.
This includes Forskolin, an activator of adenylate cyclase
resulting in an increase in c-AMP, as well as Dorsomorphin,
an inhibitor of BMP signaling. The combination of these two
small molecules has been demonstrated to enhance neuronal
reprogramming using NGN2 or SOX11 (Liu et al., 2013).
In addition, inhibition of SMAD signaling (SB431542 and
noggin) and GSK3B signaling (CHIR99021) have also been
shown to promote neuronal reprogramming (Ladewig et al.,
2012). An important milestone was achieved in 2015, when
HongKui Deng’s group developed an all chemical approach
to convert mouse fibroblasts into induced neurons that
doesn’t require genetic manipulation (Li et al., 2015). The
authors demonstrated that the use of five small molecules
(ISX9, SB431542, Forskolin, CHIR99021, I-BET151) was
sufficient to rewrite the fibroblast-specific transcriptome,
activate neuronal-related genes and effectively convert
fibroblast into neurons with up to 90% efficiency in 16 days.
Subsequent work by Hu et al. (2015) extended this all-chemical
approach for neuronal reprogramming of human fibroblasts,
using a cocktail of seven small molecules: valproic acid,
CHIR99021, REPSOX, Forskolin, Sp600125, GO6983, and
Y27632. This reprogramming method allowed derivation of
human iN containing a mix of GABAergic, cholinergic and
dopaminergic neurons, and provided an alternative approach
for neuronal reprogramming without the aid of transcription
factors.
As direct reprogramming allows the conversion of cells from
distinct lineages, it is postulated that this reprogramming process
would potentially be more efficient to convert cell fates across
lineages that are closely related and more similar in nature,
compared to lineages that are distant and markedly different.
For instance, iPS cell generation using keratinocytes exhibits a
much higher efficiency compared to using fibroblasts (Aasen
et al., 2008; Piao et al., 2014). One reason for the increased
efficiency can be attributed to the nature of fibroblasts, which go
through a mesenchymal-to-epithelial transition in the process of
iPS cell reprogramming (Li et al., 2010; Takahashi et al., 2014),
whereas keratinocytes of ectodermal origin may not require
that transition. Another cellular reprogramming example across
related lineages is the conversion of glia to neurons. Early work by
Heins et al. (2002) showed that overexpression of Pax6, a master
regulator of neural specification, can induce neurogenesis in glial
cells. Further work by Heinrich and colleagues identified Ngn2 as
a reprogramming factor to convert astroglia into glutamatergic
neurons, while expression of Dlx2 induced GABAergic neurons
with mature dendrites. The reprogrammed cells expressed pan-
neuronal markers (βIII tubulin, MAP2) while the glial marker
GFAP was downregulated. Importantly, the reprogrammed
neurons were capable of establishing synapses and possessed
functional electrophysiology (Heinrich et al., 2010). Similarly,
others have highlighted the feasibility of using small molecules
to reprogram human fetal astrocytes into neurons (Zhang et al.,
2015; Gao et al., 2017).
APPLICATION OF DIRECT
REPROGRAMMING TO CONVERT CELL
LINEAGES IN VIVO
The prospect of using direct reprogramming to convert
endogenous cells in vivo into the target cells that are lost in disease
or injury provides an exciting approach for regenerative medicine
(Figure 1B). This is an emerging area of research that is attracting
enormous interest for its therapeutic potential (Srivastava and
DeWitt, 2016; Wong and Nguyen, 2017). Notably, this approach
bypasses many of the major obstacles posed by transplantation-
based regenerative strategies, such as issues with immune
rejection and the high cost involved in production of clinical
grade cells for transplantation. Instead, in vivo reprogramming
can be promoted by viral delivery of reprogramming factors,
such as an injection of adeno-associated viruses (AAVs) to the
patient. This strategy is substantially cheaper to produce, easier
to store and often an easier clinical procedure compared to cell
transplantation.
Early pioneering work has demonstrated the feasibility of
in vivo reprogramming to convert cell fates in the pancreas and
cardiac systems. A pioneering study by Zhou et al. (2008) showed
the reprogramming of pancreatic exocrine cells into β-cells in
diabetic adult mice by using a combination of three transcription
factors (Ngn3, Pdx1, and Mafa). Remarkably, the induced β-cells
improve insulin production in the diabetic mice, demonstrating a
great potential for using direct reprogramming as a regenerative
strategy to treat diabetes (Zhou et al., 2008). A subsequent
study has identified the use of Ngn3 and Mafa for in vivo
reprogramming to convert pancreatic acinar cells into δ- or α-like
endocrine cells (Li et al., 2014) and advanced the discovery of
transcription factors that allow direct reprogramming to generate
a panel of pancreatic cell types in vivo.
In the cardiac system, Qian et al. (2012) demonstrated that
cardiac fibroblasts can be reprogrammed into cardiomyocytes
in vivo by using transcription factors Gata4, Mef2c, and Tbx5.
The induced cardiomyocytes possess similar characteristics
of binucleation, sarcomere assembly, electrical coupling, and
gene expression profile typical of cardiomyocytes. Using a
mouse myocardial infarction model, the authors injected a
retrovirus carrying GMT into the infarct site and found
that the infarct area was diminished. Notably, about 35%
of the cardiomyocytes in the marginal area of the infarct
were reprogrammed from cardiac fibroblasts. The induced
cardiomyocytes can express the functional characteristics of
adult ventricular muscles; about half of them have an organized
sarcomere structure that improves cardiac function 2–3 months
after myocardial infarction. Concurrently, Song et al. (2012)
showed the use of a similar cocktail (Gata4, Mef2c, Hand2, Tbx5)
to successfully reprogram non-cardiomyocytes into induced
cardiomyocytes in mice. Similarly, in vivo reprogramming
of cardiac fibroblasts to induced cardiomyocytes can also
be achieved with miRNAs (Jayawardena et al., 2012). The
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induced cardiomyocytes can attenuate cardiac dysfunction after
myocardial infarction. Collectively, these studies demonstrated
the use of in vivo reprogramming for cardiomyocyte regeneration
which would have important therapeutic implications for
myocardial infarction.
Another interesting research direction is the use of in vivo
reprogramming technologies to rejuvenate aging cells. It is
widely established that the use of the Yamanaka factors (Oct4,
Sox2, Klf4, and c-Myc) can reprogram somatic cells into iPS
cells – a reprogramming process that reverses many aspects
of aging signatures in the target cells, including reorganization
of mitochondria and reconstituted telomerase activity (Rohani
et al., 2014). Overexpression of the Yamanaka factors in vivo
allowed generation of iPS cells in mice, however this resulted
in teratoma formation in multiple organs (Abad et al., 2013).
Ocampo et al. (2016) overcame this issue of tumorigenicity
using an inducible system to repeatedly induce short-term
expression of the Yamanaka factors in mice. Interestingly,
this strategy prevented teratoma formation in the mice.
Using a premature aging mouse model for Hutchinson-
Gilford progeria syndrome, the author showed that this partial
reprogramming strategy reversed the cellular and physiological
hallmarks of aging, such as DNA damage and epigenetic
dysregulation, and strikingly extended the lifespan of these
mice by ∼30%. Furthermore, this reprogramming approach
also allowed wild type aged mice to increase resistance to
metabolic disease and muscle injury. These results supported
the use of short-term induction of Yamanaka factors for
partial reprogramming to rejuvenate aged cells, and provided
exciting possibilities of using regenerative medicine for anti-
aging.
IN VIVO REPROGRAMMING FOR
REGENERATION OF THE CENTRAL
NERVOUS SYSTEM
In vivo reprogramming in the nervous system has advanced
rapidly since 2013. Transcription factor-based reprogramming
to induce neurogenesis in the brain in vivo has tremendous
potential as a novel approach for neural repair in an injury or
disease setting. For instance, Grande et al. (2013) showed that
Neurog2 can be used for in vivo reprogramming to generate
new neurons in the neocortex and striatum following a stab
wound or ischemia. The addition of FGF2 and EGF was found
to enhance this process and generate more neurons in vivo.
Interestingly, the outcome of this neuronal reprogramming
in vivo was highly dependent on location; in vivo reprogramming
in the striatum only induced a small number of neurons, whereas
in vivo reprogramming in the neocortex induced a large number
of immature neurons, but only a small number of neurons
matured to a later stage. However, the precise cell types that were
targeted for reprogramming remain unclear in this study, as the
retroviruses used in this study did not deliver reprogramming
factors to a specific cell type in the brain. Future studies with the
use of cell type-specific promoter to induce reprogramming will
help address this issue.
In the nervous system, many studies have targeted the
glial cells for in vivo reprogramming into neurons. An early
study by Niu et al. (2013) demonstrated in vivo neuronal
reprogramming with lentiviral delivery of a single transcription
factor – Sox2. Sox2 alone was sufficient to reprogram striatal
astrocytes into neuroblasts within the adult mouse brain.
Subsequent addition of BDNF and noggin can direct the
induced neuroblasts to develop into electrophysiologically
mature neurons (Niu et al., 2013). Concurrently, Torper et al.
(2013) reported a glial-neuron reprogramming approach that did
not require treatment with neurotrophic factors. The authors
demonstrated that lentiviral delivery of Ascl1, Brn2, and Myt1l
into the striatal astrocytes of the mouse brain converted
them into neurons, with a reported efficiency of up to ∼6%
(Torper et al., 2013). The induced neurons exhibit neuronal
morphology and express NeuN, but are otherwise not well-
characterized. A follow up study by the same group reported
an improved method for neuronal reprogramming (Torper
et al., 2015). This improved method utilized AAV delivery
of Ascl1, Lmx1a, and Nurr1 into striatal NG2 glia, which
resulted in induced neurons with functional electrophysiological
properties. Using modified rabies virus to trace cell-cell
connectivity, the authors demonstrated that the induced neurons
successfully integrated into the existing host circuitry, with an
average of innervation by 3–4 host neurons. This confirmed
synaptogenesis between existing host afferent inputs and the
newly formed in vivo reprogrammed neurons (Torper et al.,
2015). Subsequent study by Pereira et al. (2017) showed
that the NG2 glia-derived induced neurons reach functional
maturation after 12 weeks following in vivo reprogramming,
with properties similar to fast-spiking, parvalbumin-containing
interneurons.
Whilst the in vivo reprogramming studies discussed above
targeted quiescent glial cells, other studies targeted the reactive
glial cells, which are apparent in disease or injury settings.
Using a stab wound injury model to elicit activation of glial
cells, Heinrich et al. (2014) showed that sole addition of Sox2
can induce conversion of reactive glia into induced neurons
in the adult mouse cerebral cortex. This demonstrated the
potential for using in vivo reprogramming for cortical repair of
acute injury. Although the induced neurons possess functional
electrophysiological properties, the authors noted that many
of the induced neurons lack neuronal subtype-specific traits
such as neurotransmitter release, which may suggest that the
reprogrammed cells are in an immature state. Similarly, Guo
et al. (2014) provided experimental evidence that overexpression
of Neurod1 can reprogram reactive glial cells to neurons in
the cortex of a stab-injured or Alzheimer’s disease model. This
Neurod1-mediated reprogramming is highly efficient, with a
reported efficiency of > 90%. Interestingly, the authors showed a
differential effect of Neurod1 in the reprogramming of different
glial cells. While astrocytes were mostly reprogrammed into
glutamatergic neurons, NG2 glial cells were reprogrammed
into both glutamatergic and GABAergic neurons. Collectively,
these studies demonstrate a potential therapeutic approach to
regenerate neurons and restore lost neuronal function in an
injured or diseased brain. Moreover, in vivo reprogramming
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strategies targeting reactive glial cells for conversion into neurons
may also be used to reduce reactive gliosis and reduce glial scarring
following injury in the nervous system (Li and Chen, 2016).
USING IN VIVO REPROGRAMMING FOR
RETINAL REGENERATION
Similar advances have been made for in vivo reprogramming in
the retina. The major glial cells in the retina, Müller glia (MG),
have been shown in a number of species to have the ability to
convert into new neurons. In teleost fish and postnatal chickens,
upon retinal stresses, MG can dedifferentiate to multipotent
progenitors and give rise to all retinal neural cell types to promote
retinal regeneration (Fischer and Reh, 2001; Goldman, 2014). In
rodents, acute retinal stresses can stimulate MG to proliferate and
produce a small number of neurons in vivo (Jadhav et al., 2009).
These studies support the notion that, given the appropriate
stimuli, the MG possess the plasticity to become retinal neurons,
and as such are an ideal target for testing the feasibility of in vivo
reprogramming to regenerate retinal neurons.
Pioneering studies from the Reh laboratory have paved ways
for using transcription factor-based reprogramming of MG into
retinal neurons in vivo. Their work showed that following
retinal injury, overexpression of Ascl1 in transgenic mice can
reprogram MG into retinal neurons, including photoreceptors,
bipolar and amacrine cells (Ueki et al., 2015). However, this
reprogramming is only observed in young mice (day 7) and the
neurogenic capacity of MG is lost by day 16. Subsequently, an
important improvement was reported by the same laboratory.
The addition of a histone deacetylase inhibitor Trichostatin A,
combined with Ascl1 overexpression following retinal injury,
allowed in vivo reprogramming of MG to neurons in adult mice
up to 8 months old (Jorstad et al., 2017). Using an elegant
Cre-loxP system, the authors expressed Ascl1 specifically in MG
and traced their conversion to retinal neurons in vivo. The
authors also provided evidence that addition of Trichostatin
A enabled epigenetic changes that allow expression of other
retinal neuronal genes, such as Otx2, that presumably facilitate
this in vivo reprogramming process. Notably, the reprogrammed
neurons are mostly bipolar cells and are able to form synaptic
connections with the existing retinal circuitry and respond to
visual stimuli. These results provide a major step toward using
in vivo reprogramming to regenerate the retina.
A more recent study by Yao et al. (2018) built on
this in vivo reprogramming strategy to direct MG into rod
photoreceptors. Using a two-step reprogramming method, the
authors used AAV to first overexpress beta catenin to stimulate
MG proliferation, then overexpress a cocktail of Otx2, Crx, and
Nrl for differentiation into rod photoreceptors. The MG-derived
rod photoreceptors formed functional synapses and are able
to functionally integrate into the visual pathway. Although the
reprogramming efficiency is difficult to assess in vivo, remarkably
the authors showed that this reprogramming process regenerated
sufficient rod photoreceptors to restore visual functions in
a photoreceptor degeneration mouse model, which included
restoration of responses to light and transmission of visual signals
to the primary visual cortex. Notably, the demonstration of using
AAV for MG reprogramming, as well as functional recovery in a
disease model provided a major step toward clinical development
of cell therapies to replace retinal neurons, which have important
implications in treatment of retinal degenerative diseases.
It is worth noting that the therapeutic potential of in vivo
reprogramming is not limited to generating cells that were
lost in injury or disease. In vivo reprogramming can also be
used to intervene disease progression. For instance, Montana
et al. (2013) demonstrated that transgenic knockout of Nrl,
an essential transcription factor for the formation of rod
photoreceptors during development, can partially reprogram
adult mouse rods into cones in vivo. Interestingly, by preventing
secondary cone loss, this reprogramming strategy rescued cone
function and achieved an improvement in the vision of a mouse
model of retinitis pigmentosa. Since then, two follow-up studies
have confirmed this finding and improved the reprogramming
method, by using AAV-mediated CRISPR/Cas9 to knockout
Nrl and preserve cone functions in multiple mouse models
of photoreceptor degeneration (Yu et al., 2017; Zhu et al.,
2017). Based on this concept of converting rod into cone
photoreceptors, another study has highlighted the potential of
developing small molecules to inhibit the rod photoreceptor
gene Nr2e3 to treat retinitis pigmentosa (Nakamura et al.,
2016). Collectively, this cone-to-rod reprogramming approach
represents an exciting direction with promising results that
warrant further investigation.
APPLICATION OF CELLULAR
REPROGRAMMING FOR
NEUROREGENERATION: CLINICAL
TRANSLATION AND CHALLENGES
In degenerative diseases or injuries that affect the central
nervous system, often there is no cure or effective treatment
once the neural cells are lost. Regenerative medicine offers a
promising approach to replace or regenerate the lost cells to
restore normal functions in the patients. Several strategies have
been proposed for neuroregeneration (Table 1), including cell
replacement therapies using cells from donors, cells derived
from pluripotent stem cells, or cells derived from direct
reprogramming in vitro. Compared to pluripotent stem cell
differentiation, direct reprogramming in vitro offers a potentially
faster and more cost-effective approach to generate patient-
specific cells for transplantation. Also, the recent development
of in vivo reprogramming represents a novel approach for
regenerative medicine, by stimulating endogenous cells to
replace the cells lost in diseases/injuries. Notably, transcription
factor-based reprogramming in vivo would follow the clinical
development pathway of gene therapy which is highly attractive
commercially (de Wilde et al., 2016), as opposed to cell
replacement therapy which incurs high cost associated with
production of clinical grade cells. It is clear that there are
great opportunities of developing novel regenerative strategies
using in vivo reprogramming. However, there are also significant
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TABLE 1 | Comparison of different strategies for neuroregeneration.
Strategy Category Preparation/availability Cost GMP cell Advantages Disadvantages
facility?
Transplantation using
donor cells
Cell based Dependent on donor
availability
$ No – Allogeneic transplantation
– Avoid risks of mutations induced
by in vitro culture
– Suitable for treatment of genetic
diseases
– Often donor shortage
– Cell quantity limited by donor
tissue
– Risk of graft rejection
Transplantation using
cells derived from
donor ESC/iPSC
Cell based PSC can be differentiated
and stored as frozen cells,
thawed and expanded on
demand
$$ Yes – Allogeneic transplantation
– PSC represent a renewable
cellular source
– Potential to upscale cell
production
– A bank of limited number of PSC
cell lines can potentially provide
HLA matching for a large portion
of the population
– Suitable for treatment of genetic
diseases
– Requires meticulous quality
control for derived cells
– Risk of teratoma formation
– Long time required for iPSC
generation and subsequent stem
cell differentiation
– Risk of mutations arise during
in vitro culture
– Needs HLA matching to address
immunorejection issues
Transplantation using
cells derived from
patient-specific iPSC
Cell based Requires extraction of
patient cells, iPSC
generation and subsequent
differentiation
$$$$ Yes – Autologous transplantation
– PSC represent a renewable
cellular source
– Potential to upscale cell
production
– Potential for development of
disease modeling, personalized
drug discovery and gene therapy
– Requires meticulous quality
control for derived cells
– Risk of teratoma formation
– Long time required for iPSC
generation and subsequent stem
cell differentiation
– Risk of mutations arise during
in vitro culture
– For genetic diseases would
requires combined gene therapy
Transplantation using
cells derived from direct
reprogramming in vitro
Cell based Requires extraction of
patient cells and direct
reprogramming in vitro
$$ Yes – Autologous transplantation
– Potentially faster than iPSC
generation and subsequent
differentiation
– Less risk of tumorigenicity
– Potential for development of
disease modeling, personalized
drug discovery and gene therapy
– Requires meticulous quality
control for derived cells
– Risk of mutations arise during
in vitro culture
– Non-renewable cellular source:
limited cell quantity
– For genetic diseases would
requires combined gene therapy
Direct reprogramming
in vivo
Gene based Viral vectors can be stored
as off-the shelf treatment
$ No – Bypass transplantation
– Less risk of tumorigenicity
– Avoid risks of mutations induced
by in vitro culture
– Possible depletion of
endogenous cell pool following
reprogramming
– For genetic diseases would
requires combined gene therapy
PSCs, pluripotent stem cells; ESCs, embryonic stem cells; iPSCs, induced pluripotent stem cells; HLA, human leukocyte antigen.
hurdles that need to be overcome before this technology can
translate into the clinics. Here we will discuss some of these
hurdles for in vivo reprogramming and potential solutions for
these issues.
a) Potential Risk of Endogenous Cell
Depletion
In order to achieve functional rescue in disease or injury, often
a sizeable number of cells must be regenerated. Understandably,
this may lead to the depletion of endogenous cells that were
reprogrammed. This is an important consideration for using
in vivo reprogramming for regeneration. To what extent, if any,
will normal function be compromised with the repurposing of
these cells? Will the remaining population be sufficient to carry
out their functional roles? Careful selection of the target cell for
reprogramming is therefore necessary. For instance, targeting
cell types with a large number of cells, or a cell type whose
pool is continually replenished under homeostasis, would be
advantageous in the application of in vivo reprogramming.
b) Reprogrammed Cells May Still Harbor
Genetic Mutations
In degenerative diseases that are caused by genetic mutation(s),
it is important to consider that while in vivo reprogramming
may regenerate cells that were lost, the reprogrammed cells will
still harbor the disease-causing mutation and can be prone to
degeneration in the future. In this regard, it can be argued
that disease-mediated degeneration may take years to manifest,
and as such in vivo reprogramming can be used as a temporal
treatment. Alternatively, a combination of gene therapy and
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 November 2018 | Volume 12 | Article 460
fncel-12-00460 November 28, 2018 Time: 19:30 # 8
Fang et al. Neuroregeneration Using Cellular Reprogramming
in vivo reprogramming, as demonstrated by Yao et al. (2018) in
retinal glial cells, will allow for both the correction of genetic
mutation(s) and cell replacement in hereditary degenerative
diseases.
c) Identification of Reprogramming
Factors
A major limitation is the identification of reprogramming factors
that promote conversion to a specific target cell type. The
conventional strategy is to screen through a list of transcription
factors that are important for the development of the target
cells to identify the factors that allow cellular reprogramming.
However, this is a time-consuming and laborious process.
To address this issue, several groups have reported on the
development of computational algorithm to analyze gene
regulatory networks to predict the transcription factors that
promote cellular reprogramming. One example is Mogrify,
which predicts and ranks transcription factors based on their
transcriptional regulatory influence on the target cell type by
enrichment and network topology analysis (Rackham et al.,
2016). Another recent algorithm incorporates cell cycle features
to improve the prediction of reprogramming factors and ideal
timing for the introduction of these factors during the direct
reprogramming process (Ronquist et al., 2017).
d) Gene Delivery Systems for
Reprogramming Factors
Another consideration for the clinical translation of in vivo
reprogramming is the gene delivery system. Ideally, delivery of
reprogramming factors should be safe, effective, and specific to
the target cells. A marker-specific promoter can be incorporated
into the vector design to achieve cell specific expression of
reprogramming factors and minimize off-target effects of in vivo
reprogramming. There are numerous methods commonly used
to deliver the genes, including lentivirus/retrovirus, adenovirus,
AAV, and liposomes. Lentivirus and retrovirus allow delivery of
larger insert, but given their nature to integrate into the host
genome they are less desirable to be used for gene therapy.
Of the integration-free viral delivery systems, AAV is a very
attractive gene delivery system for gene therapy, with mounting
evidence supporting its safety and effectiveness in preclinical and
clinical settings (Naso et al., 2017). Moreover, AAV with different
serotypes show varying transduction efficiency that are cell type
dependent (Balaji et al., 2013), a characteristic which can be used
to promote specific gene expression in a target cell type. However,
AAV has a ∼5 kb limit on the insert size (Björklund et al., 2000),
thus often this is not suitable for co-expression of more than one
transgene. Further development and modification of AAV will be
an exciting direction to improve the specificity of transduction in
target cells.
Alternatively, another potential solution is to use
small molecules to replace transcription factors for
in vivo reprogramming (Li et al., 2018). Although in vivo
reprogramming in the neural systems with an all-chemical
approach is still in its infancy, this is an attractive reprogramming
strategy for clinical translation, as small molecules can be cost-
effective, non-immunogenic, produced in high quantity and
efficiently delivered across the membrane into cells. Future
studies in this direction would be very exciting with high
potentials for clinical translation.
e) Tracking and Analyzing Cellular
Reprogramming in vivo
It is imperative to distinguish newly reprogrammed cells from the
resident cells within the tissue. To address this, the gene delivery
vector can be designed to incorporate a fluorescent tag, such as
the Cre-loxP system, for lineage tracing of the cell conversion
in vivo. In many cases, the reprogramming efficiency in vivo may
be low, thus the analysis techniques utilized have to be sufficiently
sensitive to address this. The emergence of single cell analysis
provides an exciting technology to understand the process of
in vivo reprogramming. For instance, the recent advances in
microfluidic technology have greatly enhanced the throughput
of single cell transcriptome analysis (Stubbington et al., 2017).
Single cell transcriptome analysis is highly suitable to analyze the
process of cellular reprogramming which is often inefficient. We
expect to see more utilization of single cell RNA sequencing in
the coming years.
CONCLUDING REMARKS
Rapid advances in the field of cellular reprogramming have
created a new paradigm for regenerative medicine. Direct
reprogramming provides a feasible method to generate
cells in vitro for biological studies, tissue engineering
or transplantation. Moreover, the application of direct
reprogramming in vivo provides an exciting regenerative
strategy to reprogram and repurpose endogenous cells within
damaged tissues, which overcomes limitations associated
with transplantation of donor cells. The studies outlined
here demonstrate advances in their respective fields and
collectively demonstrate an exciting progress of applying cellular
reprogramming for regenerative medicine. Future studies to test
the therapeutic potential of in vivo reprogramming in animal
disease models or injury models would be of high interest. We
expect that the development of better computational methods
would improve prediction of transcription factors to convert cell
fates and advance the field of cellular reprogramming. Other
emerging new technologies, such as single cell transcriptome
analysis and new CRISPR/Cas systems to modulate gene
expression, would provide new tools to better understand the
cellular reprogramming process, improve the specificity and
efficiency of cellular reprogramming and facilitate the clinical
application of this technology for regenerative medicine.
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